Details of the Drug Reposition

General Information of This Drug (ID: DMCBJSR)

Drug Name
Sunitinib   DMCBJSR
Synonyms
Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
13 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Salivary gland squamous cell carcinoma DISDI0CT N.A. Approved [1]
Prostate adenocarcinoma DISBZYU8 N.A. Approved [1]
Classic Kaposi sarcoma DISN895I N.A. Approved [1]
Chronic myelomonocytic leukemia DISIL8UR N.A. Approved [1]
Acute undifferentiated leukemia DISJ4SSG N.A. Approved [1]
Refractory chronic myeloid leukaemia DIS40YPP 2A20 Approved [1]
Mast cell leukaemia DIS7VQW9 2A21.00 Approved [1]
Prolymphocytic leukaemia DISDPPHX 2A82.1 Approved [1]
Large granular lymphocytic leukemia DISHOPPI 2A90.1 Approved [1]
Gastrointestinal stromal tumour DIS6TJYS 2B5B Approved [2]
Pancreatic cancer DISJC981 2C10 Approved [1]
Gastrointestinal cancer DISHIGUN 2C11 Approved [3]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Indications(s)
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pancreatic endocrine carcinoma DISYZ23O N.A. Withdrawn [4]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Renal cell carcinoma DISQZ2X8 2C90 Discontinued in Phase 3 [5]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neuroendocrine neoplasm DISNPLOO N.A. Discontinued in Phase 2 [6]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Plexiform neurofibroma DISW4XX7 N.A. Investigative [1]
------------------------------------------------------------------------------------

References

1 Sunitinib FDA Label
2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5713).
4 Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
5 A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
6 Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)